Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis

International Journal of Oncology

Volumn 37, Issue 3, 2010, Pages 563-567

  Holmberg, Anders R ^a   Lerner, Ulf H ^c,d   Alayia, Ayodele A ^b   Al Mohanna, Mai ^b   Adra, Chaker ^b   Marquez, Marcela ^a   Meurling, Lennart ^a   Sten, Nilsson ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bone metastasis; Breast cancer; Poly bisphosphonate; Prostate cancer

Indexed keywords

ALENDRONIC ACID PLUS AMINOGUANIDINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM 45; DEXTRAN 40; GUANIDINE; LIPOCORTIN 5; POLYBISPHOSPHONATE CONJUGATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

AMINATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE MINERAL; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FLUORESCENCE; HUMAN; HUMAN CELL; MALE; MOUSE; NEWBORN; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OXIDATION; PRIORITY JOURNAL;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MICE; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 77956501550     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000705     Document Type: Article

References (21)

1. Buijs JT and van der Pluijm G: Osteotropic cancers: from primary tumor to bone. Cancer Lett 273: 177-193, 2009.
2. Paget S: The distribution of secondary growths in cancer of the breast 1889. Cancer Metastasis Rev 8: 98-101, 1989.
3. Bussard KM, Gay CV and Mastro AM: The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 27: 41-55, 2008.
4. Lambrinoudaki I, Christodoulakos G and Botsis D: Bisphosphonates. Ann N Y Acad Sci 1092: 397-402, 2006.
5. Saad F and Sternberg CN: Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nat Clin Prac Urol 4: S3-S13, 2007. (Pubitemid 46206540)
6. Gralow J and Tripathy D: Managing metastatic bone pain: the role of bisphosphonates. J Pain Symptom Manage 33: 462-472, 2007.
7. Hoesl CE and Altwein JE: Bisphosphonates in advanced prostate and renal cell cancer - current status and potential applications. Urol Int 76: 97-105, 2006
8. Brown JE and Coleman RE: The role of bisphosphonates in breast cancer: the present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Res 4: 24-29, 2002.
9. Neville-Webbe HL, Evans CA, Coleman RE and Holen I: Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biol 27: 92-103, 2006.
10. Dearnaley DP, Mason MD, Parmar MKB, Sanders K and Sydes MR: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PRO4 and PRO5 randomised controlled trials. Lancet Oncol 10: 872-876, 2009.
11. Marquez M, Nilsson S, Lennartsson L, Liu Z, Tammela T, Raitanen M and Holmberg AR: Charge-dependent targeting: results in six tumor cell lines. Anticancer Res 24: 1347-1352, 2004.
12. Larsson R and Nygren P: A rapid fluorometric method for semi-automated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res 9: 1111-1119, 1989.
13. Lerner UH: Modifications of the mouse calvarial technique improve the responsiveness to stimulators of bone resorption in vitro. J Bone Min Res 2: 375-383, 1987.
14. Ljunggren Ö, Ransjö M and Lerner UH: In vitro studies on bone resorption in neonatal mouse calvariae using a modified dissection technique giving four samples of bone from each calvariae. J Bone Miner Res 6: 543-550, 1991.
15. Conaway HH, Grigorie D and Lerner UH: Differential effects of glucocorticoids on bone resorption in neonatal mouse calvariae stimulated by peptide and steroid-like hormones. J Endocrinol 155: 513-521, 1997. (Pubitemid 27524058)
16. Owens G, Jackson R and Lewiecki M: An integrated approach: bisphosphonate management for the treatment of osteoporosis. Am J Manag Care 13: S290-S308, 2007.
17. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonate. JPET 296: 235-242, 2001.
18. Zhang Y, Cao R, Yin F, Hudock MP, Guo RT, Krysiak K, Mukherjee S, Gao YG, Robinson H, Song Y, No JH, Bergan K, Leon A, Cass L, Goddard A, Chang TK, Lin FY, Van Beek E, Papapoulos S, Wang AHJ, Kubo T, Ochi M, Mukkamala D and Oldfield E: Lipophilic bisphosphonates as dual farnesyl/ geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc 131: 5153-5162, 2009.
19. Ullén A, Lennartsson L, Hamenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B and Nilsson S: Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Act Oncol 44: 644-650, 2005.
20. Neville-Webbe H, Rostami-Hodjegan A, Evans CA, Coleman RE and Holen I: Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113: 364-371, 2005. (Pubitemid 40038702)
21. Meurling L, Márquez M, Nilsson S and Holmberg AR: Polymer-conjugated guanidine is a potentially useful anti-tumor agent. Int J Oncol 35: 281-285, 2009.